BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 22422409)

  • 1. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.
    Meric-Bernstam F; Akcakanat A; Chen H; Do KA; Sangai T; Adkins F; Gonzalez-Angulo AM; Rashid A; Crosby K; Dong M; Phan AT; Wolff RA; Gupta S; Mills GB; Yao J
    Clin Cancer Res; 2012 Mar; 18(6):1777-89. PubMed ID: 22422409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.
    Seront E; Pinto A; Bouzin C; Bertrand L; Machiels JP; Feron O
    Br J Cancer; 2013 Sep; 109(6):1586-92. PubMed ID: 23989949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.
    Citi V; Del Re M; Martelli A; Calderone V; Breschi MC; Danesi R
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):745-754. PubMed ID: 29476223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
    Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y
    PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
    Elkabets M; Vora S; Juric D; Morse N; Mino-Kenudson M; Muranen T; Tao J; Campos AB; Rodon J; Ibrahim YH; Serra V; Rodrik-Outmezguine V; Hazra S; Singh S; Kim P; Quadt C; Liu M; Huang A; Rosen N; Engelman JA; Scaltriti M; Baselga J
    Sci Transl Med; 2013 Jul; 5(196):196ra99. PubMed ID: 23903756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.
    Yeung Y; Lau DK; Chionh F; Tran H; Tse JWT; Weickhardt AJ; Nikfarjam M; Scott AM; Tebbutt NC; Mariadason JM
    Mol Oncol; 2017 Sep; 11(9):1130-1142. PubMed ID: 28544747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
    Gökmen-Polar Y; Liu Y; Toroni RA; Sanders KL; Mehta R; Badve S; Rommel C; Sledge GW
    Breast Cancer Res Treat; 2012 Dec; 136(3):673-82. PubMed ID: 23085766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.
    Breuleux M; Klopfenstein M; Stephan C; Doughty CA; Barys L; Maira SM; Kwiatkowski D; Lane HA
    Mol Cancer Ther; 2009 Apr; 8(4):742-53. PubMed ID: 19372546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
    Weigelt B; Warne PH; Downward J
    Oncogene; 2011 Jul; 30(29):3222-33. PubMed ID: 21358673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.
    Treilleux I; Arnedos M; Cropet C; Wang Q; Ferrero JM; Abadie-Lacourtoisie S; Levy C; Legouffe E; Lortholary A; Pujade-Lauraine E; Bourcier AV; Eymard JC; Spaeth D; Bachelot T
    Ann Oncol; 2015 Jan; 26(1):120-125. PubMed ID: 25361980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
    Xing Y; Lin NU; Maurer MA; Chen H; Mahvash A; Sahin A; Akcakanat A; Li Y; Abramson V; Litton J; Chavez-MacGregor M; Valero V; Piha-Paul SA; Hong D; Do KA; Tarco E; Riall D; Eterovic AK; Wulf GM; Cantley LC; Mills GB; Doyle LA; Winer E; Hortobagyi GN; Gonzalez-Angulo AM; Meric-Bernstam F
    Breast Cancer Res; 2019 Jul; 21(1):78. PubMed ID: 31277699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
    Javle MM; Shroff RT; Xiong H; Varadhachary GA; Fogelman D; Reddy SA; Davis D; Zhang Y; Wolff RA; Abbruzzese JL
    BMC Cancer; 2010 Jul; 10():368. PubMed ID: 20630061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.
    Yunokawa M; Koizumi F; Kitamura Y; Katanasaka Y; Okamoto N; Kodaira M; Yonemori K; Shimizu C; Ando M; Masutomi K; Yoshida T; Fujiwara Y; Tamura K
    Cancer Sci; 2012 Sep; 103(9):1665-71. PubMed ID: 22703543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.
    Janku F; Hong DS; Fu S; Piha-Paul SA; Naing A; Falchook GS; Tsimberidou AM; Stepanek VM; Moulder SL; Lee JJ; Luthra R; Zinner RG; Broaddus RR; Wheler JJ; Kurzrock R
    Cell Rep; 2014 Jan; 6(2):377-87. PubMed ID: 24440717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling.
    He X; Wang Y; Zhu J; Orloff M; Eng C
    Cancer Lett; 2011 Feb; 301(2):168-76. PubMed ID: 21168265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
    Cloughesy TF; Yoshimoto K; Nghiemphu P; Brown K; Dang J; Zhu S; Hsueh T; Chen Y; Wang W; Youngkin D; Liau L; Martin N; Becker D; Bergsneider M; Lai A; Green R; Oglesby T; Koleto M; Trent J; Horvath S; Mischel PS; Mellinghoff IK; Sawyers CL
    PLoS Med; 2008 Jan; 5(1):e8. PubMed ID: 18215105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wild-type phosphatase and tensin homolog deleted on chromosome 10 improved the sensitivity of cells to rapamycin through regulating phosphorylation of Akt in esophageal squamous cell carcinoma.
    Lu Z; Wang J; Zheng Y; Yang S; Liu M; Chen X; Wang C; Hou G
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26725440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.